



Summary
2nd Quarter FY 17-18 Medication Monitoring Report
Adult/Older Adult System of Care

Of the 42 programs that report on Medication Monitoring, 98% submitted a report. The program that did not submit a report was still in start up during Q2.

A total of 7956 charts were reported open to meds in the quarter.


A total of 129 charts were reviewed (2% of open charts).

A total of 67 variances were reported (2% of possible variances in reviewed charts). The majority of variances are in the areas of labs (2b-2f), and informed consent (6).

The variances break out as follows (the number to the right represents programs who answered no and thus had a variance):

1	Medication rationale and dosage is consistent with the community standards.	2
2a	Were labs indicated? NOTE: A "NO" answer to this question is not considered a variance. If this question is answered with "NO", the rest of the questions under 2 (b - f) should be N/A.	
2b	Were lab results obtained?	12
2c	Were labs reviewed by Medical Staff?	2
2d	Were lab results present in the chart?	8
2e	Were attempts made to obtain appropriate labs?	3
2f	If treatment continues without labs, is there appropriate rationale to continue or discontinue meds?	4
3	Physical health conditions and treatment are considered when prescribing psychiatric medication.	2
4	No more than 1 of each chemical class concurrently without a clearly documented rationale.	4
5	Were Adverse Drug Reactions and/or Side Effects treated and managed effectively?	0
6	Informed consent is evidenced by a signed consent form.	15
7	Diagnosis in concordance with prescribed medication.	0
8a	MD Documentation includes Client Response to medication therapy.	0
8b	MD Documentation includes Presence/absence of side effects.	3
8c	MD Documentation includes Extent of client's adherence with the prescribed medication regimen and relevant interventions.	4
8d	MD Documentation includes Client's degree of knowledge regarding management of his/her medication(s).	1
9	Benzodiazapine Criteria: Dose is within community standards of FDA Guidelines.	0
10	Documentation shows absence of BZD abuse.	1
11	For long-term use of BZD medication, rationale is documented based on previous failures on other treatment medications or modalities.	3
12	No more than one antiolytic is prescribed without a clearly documented rationale.	0
13	If treatment is for short-term use as a sleep aid, documentation shows evidence that patient has failed previous non-BZD medications.	2
14	If patient is requesting medication between doctor visits or escalating doses without physician approval, interventions to address these behaviors are documented.	1

**AOA Mental Health Services Providers
Medication Monitoring
Number and Type of Variances
System Wide Cumulative
Q1 - Q4 FY 2017-18**



1.54%

Type of Variance	1	2b	2c	2d	2e	2f	3	4	5	6	7	8a	8b	8c	8d	9	10	11	12	13	14	Total Variance	Total Charts Review
First Quarter	0	9	6	8	4	1	2	6	1	10	2	2	4	2	2	0	2	1	1	0	0	63	126
Second Quarter	2	12	2	8	3	4	2	4	0	15	0	0	3	4	1	0	1	3	0	2	1	67	129
Third Quarter																							
Fourth Quarter																							
Totals	2	12	8	16	7	5	4	10	1	25	2	2	7	6	3	0	3	4	1	2	1	130	255


VARIANCE QUESTION KEY

- 1. Medication rationale and dosage is consistent with community standards.
- 2a. Were Labs indicated? NOTE: A "NO" answer to this question is not considered a variance. If this question is answered with "NO", the rest of the questions under 2 (b - f) should be N/A
- 2b. Were lab results obtained?
- 2c. Were labs reviewed by Medical Staff?
- 2d. Were lab results present in chart?
- 2e. Were attempts made to obtain appropriate labs?
- 2f. If treatment continues without labs, is there appropriate rationale to continue or discontinue meds?
- 3. Physical Health conditions and treatment considered when prescribing psychiatric medication.
- 4. No more than 1 of each chemical class concurrently without a clearly documented rationale.
- 5. Adverse Drug Reactions and/or side effects treated and managed effectively.
- 6. Informed consent is evidenced by a signed consent form.
- 7. Diagnosis in concordance with prescribed medication.
- 8a. MD Documentation includes Client Response to medication therapy.
- 8b. MD Documentation includes Presence/absence of side effects.
- 8c. MD Documentation includes Extent of client's adherence with the prescribed medication regimen and relevant interventions.
- 8d. MD Documentation includes Client's degree of knowledge regarding management of his/her medication(s).
- 9. Benzodiazepine Criteria: Dose is within community standards of FDA Guidelines.
- 10. Documentation shows absence of BZD abuse.
- 11. For long-term use of BZD medication, rationale is documented based on previous failures on other treatment medications or modalities.
- 12. No more than one antiolytic is prescribed without a clearly documented rationale.
- 13. If treatment is for short-term use as a sleep aid, documentation shows evidence that patient has failed previous non-BZD medicatons.
- 14. If patient is requesting medication between doctor visits or escalating doses without physician approval, interventions to address these behaviors are documented.

**AOA MENTAL HEALTH SERVICES PROVIDER
MEDICATION MONITORING**

Compliance Analysis - Variances 2 (Labs) and 6 (Informed Consent)

	Charts Reviewed	# Variances						Compliance Rate					
		2b	2c	2d	2e	2f	6	2b	2c	2d	2e	2f	6
1st Quarter	63	9	6	8	4	1	10	86%	90%	87%	94%	98%	84%
2nd Quarter	67	12	2	8	3	4	15	82%	97%	88%	96%	94%	78%
3rd Quarter													
4th Quarter													



2a. Were Labs indicated? NOTE: A "NO" answer to this question is not considered a variance. If this question is answered with "NO", the rest of the questions under 2 (b - f) should be N/A.

2b. Were lab results obtained?

2c. Were labs reviewed by Medical Staff?

2d. Were lab results present in chart?

2e. Were attempts made to obtain appropriate labs?


2f. If treatment continues without labs, is there appropriate rationale to continue or discontinue meds?

6. Informed consent is evidenced by a signed consent form.


**AOA MENTAL HEALTH SERVICES PROVIDERS
MEDICATION MONITORING**

Compliance Analysis (Variance 2 - Labs and Variance 6 - Informed Consent)

By Region						
	2b	2c	2d	2e	2f	6
Central	3	0	2	1	0	5
East	1	0	0	0	0	0
North Central	0	0	0	0	0	1
North Coastal	3	0	2	1	0	6
North Inland	2	2	3	1	2	3
South	3	0	1	0	2	0
Total - Var 2	29					
					Total - Var 6	15



By Level of Care						
	2b	2c	2d	2e	2f	6
Case Management	1		2	1		1
Outpatient	11	2	6	2	4	14
Residential Patch/Crisis Residential						
Total - Var 2	29					
					Total - Var 6	15



Note: The numbers reported here represent the instances of non-compliance as reported by the providers.